Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $12.48 in the prior trading day, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) closed at $12.51%, Up $0.24%. In other words, the price has increased by $0.24 from its previous closing price. On the day, 2.98 million shares were traded. SNDX stock price reached its highest trading level at $12.65 during the session, while it also had its lowest trading level at $12.1.
Ratios:
Our goal is to gain a better understanding of SNDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 2.19 whereas as Long-Term Debt/Eq ratio is at 2.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on August 05, 2025, Reiterated its Buy rating but revised its target price to $56 from $43 previously.
On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $18.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $37.UBS initiated its Buy rating on October 24, 2024, with a $37 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 16 ’25 when Goldan Keith A. sold 1,296 shares for $9.29 per share. The transaction valued at 12,033 led to the insider holds 92,450 shares of the business.
Metzger Michael A sold 7,534 shares of SNDX for $69,953 on Jul 16 ’25. The Chief Executive Officer now owns 298,661 shares after completing the transaction at $9.29 per share. On Jul 16 ’25, another insider, Goldan Keith A., who serves as the Officer of the company, bought 1,296 shares for $9.29 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1077635200 and an Enterprise Value of 954451712. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.78 while its Price-to-Book (P/B) ratio in mrq is 6.84. Its current Enterprise Value per Revenue stands at 12.247 whereas that against EBITDA is -2.815.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.68, which has changed by -0.37040764 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $22.50, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is 23.16%, while the 200-Day Moving Average is calculated to be -4.86%.
Shares Statistics:
The stock has traded on average 2.26M shares per day over the past 3-months and 3534980 shares per day over the last 10 days, according to various share statistics. A total of 86.06M shares are outstanding, with a floating share count of 82.57M. Insiders hold about 4.15% of the company’s shares, while institutions hold 116.41% stake in the company. Shares short for SNDX as of 1752537600 were 23691424 with a Short Ratio of 10.50, compared to 1749772800 on 22003021. Therefore, it implies a Short% of Shares Outstanding of 23691424 and a Short% of Float of 31.1.
Earnings Estimates
Syndax Pharmaceuticals Inc (SNDX) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.29 and low estimates of -$0.93.
Analysts are recommending an EPS of between -$2.64 and -$3.7 for the fiscal current year, implying an average EPS of -$3.09. EPS for the following year is -$1.87, with 10.0 analysts recommending between -$0.51 and -$3.01.
Revenue Estimates
10 analysts predict $48.57M in revenue for the current quarter. It ranges from a high estimate of $60.17M to a low estimate of $43.5M. As of the current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $12.5MFor the next quarter, 10 analysts are estimating revenue of $62.57M. There is a high estimate of $78.97M for the next quarter, whereas the lowest estimate is $50.9M.
A total of 10 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $194.19M, while the lowest revenue estimate was $153M, resulting in an average revenue estimate of $169.24M. In the same quarter a year ago, actual revenue was $23.68MBased on 10 analysts’ estimates, the company’s revenue will be $348.84M in the next fiscal year. The high estimate is $448.87M and the low estimate is $257.7M.
